Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14-25
SponsorStephan Eliez

About this trial

The purpose of this project is to explore the effects of transcranial alternating current stimulation (tACS) in children, adolescents and young adults with a 22q11.2 microdeletion. The main aim of the present research project is to investigate the effects of repeated, individually tuned high-density (HD) tACS on cognition (i.e., WM performance) and related neuroimaging markers in carriers of the 22q11DS. As cognitive deficits, most notably WM impairment, are among the earliest signs of psychotic disorders, interventions during adolescence aimed at reducing cognitive decline in at-risk individuals may prove effective in delaying or even preventing the later emergence of psychotic symptoms.

Eligibility criteria

Qualifiers

Confirmed genetic diagnosis of 22q11DS

Age between 14 and 25 years old

Willingness to participate

Informed Consent signed by the subject and/or the caregiver(s)

Disqualifiers

Epilepsy

Deep brain stimulation electrodes

Traumatic brain injury

Facial metal implants

Trial design

Treatments tested in this trial

  • at-home tACS using Starstim-Home tES

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Stephan Eliez

Lead sponsor

University of Geneva, Switzerland

Sponsor institution